Skip to main content
Journal cover image

NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.

Publication ,  Journal Article
Osada, T; Clay, T; Hobeika, A; Lyerly, HK; Morse, MA
Published in: Cancer Immunol Immunother
September 2006

Recent reports revealed that dendritic cell (DC)-natural killer (NK) cell interaction plays an important role in tumor immunity, but few DC vaccine studies have attempted to evaluate the non-specific, yet potentially clinically relevant, NK response to immunization. In this study, we first analyzed in vitro activation of NK cells by DCs similar to those used in clinical trials. Subsequently, NK cell responses were analyzed in a phase I clinical trial of a vaccine consisting of autologous DCs loaded with a fowlpox vector encoding CEA. The data were compared with the clinical outcome of the patients. DC enhances NK activity in vitro, partly by sustaining NK cell survival and by enhancing the expression of NK-activating receptors, including NKp46 and NKG2D. Among nine patients in our clinical trial, NK cytolytic activity increased in four (range 2.5-5 times greater lytic activity) including three who had increased NK cell frequency, was stable in two and decreased in three. NKp46 and NKG2D expression showed a good correlation with the patients' NK activity. When patients were grouped by clinical activity (stable disease/no evidence of disease (stable/NE, n=5) vs progressive disease (N=4) at 3 months), the majority in the stable/NE group had increases in NK activity (P=0.016). Anti-CEA T cell response was enhanced in all the nine patients analyzed, but was not significantly different between the two groups (P=0.14). Thus, NK responses following DC vaccination may correlate more closely with clinical outcome than do T cell responses. Monitoring of NK response during vaccine studies should be routinely performed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Immunol Immunother

DOI

ISSN

0340-7004

Publication Date

September 2006

Volume

55

Issue

9

Start / End Page

1122 / 1131

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Lymphocyte Subsets
  • Lymphocyte Activation
  • Lung Neoplasms
  • Killer Cells, Natural
  • Immunotherapy
  • Immunology
  • Humans
  • Dendritic Cells
  • Colorectal Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Osada, T., Clay, T., Hobeika, A., Lyerly, H. K., & Morse, M. A. (2006). NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother, 55(9), 1122–1131. https://doi.org/10.1007/s00262-005-0089-3
Osada, Takuya, Timothy Clay, Amy Hobeika, H Kim Lyerly, and Michael A. Morse. “NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.Cancer Immunol Immunother 55, no. 9 (September 2006): 1122–31. https://doi.org/10.1007/s00262-005-0089-3.
Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006 Sep;55(9):1122–31.
Osada, Takuya, et al. “NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.Cancer Immunol Immunother, vol. 55, no. 9, Sept. 2006, pp. 1122–31. Pubmed, doi:10.1007/s00262-005-0089-3.
Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006 Sep;55(9):1122–1131.
Journal cover image

Published In

Cancer Immunol Immunother

DOI

ISSN

0340-7004

Publication Date

September 2006

Volume

55

Issue

9

Start / End Page

1122 / 1131

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Lymphocyte Subsets
  • Lymphocyte Activation
  • Lung Neoplasms
  • Killer Cells, Natural
  • Immunotherapy
  • Immunology
  • Humans
  • Dendritic Cells
  • Colorectal Neoplasms